ES1 and other board members. Do NOT use technical analysis to give yourself a false sense of confidence. This is an extremely volatile biotech that is extremely small and extremely early stage. The stock price IS NOT a function of fundamental analysis. It is a function of the demand for shares as sort of a popularity contest and nothing more.
The fact of the matter is that the only avenue for significant amounts of incoming cash is to issue HUGE amount of shares. That is, dilution. Realize, with successful trial data being released, the Company will use that time period to issue shares. Note, they just received approval for almost a doubling of shares outstanding.
The correct point of view is not to study the value of your shares. Instead, look at how much in terms of dollars you are willing to risk in order to participate in the eventual success of trials. Only then will we have a bona fide chance in reaching shareholder profits.
Am I suggesting that folks go into paralysis by analysis? No. ACTC.OB is the right product in a HUGE worldwide need. But, it will take significantly more cash before these products start to get to market. And, it will take approvals by the FDA which is always a crapshoot.
While this stock will be volitile, it will take incredible patience in order to capitalize on this investment. Good luck.
AI
